DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know

19.03.25 23:00 Uhr

Werte in diesem Artikel
Aktien

136,35 EUR -0,40 EUR -0,29%

Indizes

5.675,3 PKT 60,6 PKT 1,08%

DaVita HealthCare (DVA) closed at $149.83 in the latest trading session, marking a +0.31% move from the prior day. This change lagged the S&P 500's 1.08% gain on the day. At the same time, the Dow added 0.92%, and the tech-heavy Nasdaq gained 1.41%.Shares of the kidney dialysis provider witnessed a loss of 3.66% over the previous month, trailing the performance of the Medical sector with its gain of 0.21% and outperforming the S&P 500's loss of 8.26%.Market participants will be closely following the financial results of DaVita HealthCare in its upcoming release. On that day, DaVita HealthCare is projected to report earnings of $1.75 per share, which would represent a year-over-year decline of 26.47%. Alongside, our most recent consensus estimate is anticipating revenue of $3.23 billion, indicating a 5.27% upward movement from the same quarter last year.For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $10.76 per share and a revenue of $13.47 billion, representing changes of +11.16% and +5.08%, respectively, from the prior year.Investors should also note any recent changes to analyst estimates for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.93% lower. DaVita HealthCare is currently sporting a Zacks Rank of #3 (Hold).In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 13.88. This represents a discount compared to its industry's average Forward P/E of 20.31.Investors should also note that DVA has a PEG ratio of 1.1 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 1.83 at yesterday's closing price.The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 40, putting it in the top 16% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf DaVita

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DaVita

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu DaVita Inc Registered Shs

Wer­bung

Analysen zu DaVita Inc Registered Shs

DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
27.04.2015DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
18.10.2011DaVita outperformRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
04.11.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
06.08.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.03.2015DaVita HealthCare Partners HoldDeutsche Bank AG
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DaVita Inc Registered Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen